Table 1.
Patient characteristics (N=24)
| Na (%) | |
|---|---|
| Age (Years) | |
| Median (range) | 57 (22–73) |
| Gender | |
| Male | 7 (29) |
| Female | 17 (71) |
| Race | |
| White | 19 (83) |
| Black | 3 (13) |
| Asian | 1 (4) |
| Unknown | 1 (4) |
| Performance status | |
| 0 | 10 (42) |
| 1 | 13 (54) |
| 2 | 1 (4) |
| Weight loss in previous 6 months | |
| <5% of body weight | 22 (92) |
| 5–10% of body weight | 2 (8) |
| Primary site | |
| Oral tongue | 1 (4) |
| Floor of mouth | 1 (4) |
| Hard palate | 3 (13) |
| Nasopharynx, NOS | 2 (8) |
| Salivary glands, NOS | 1 (4) |
| Parotid | 4 (17) |
| Submaxillary | 1 (4) |
| Ethmoid | 1 (4) |
| Nasal cavity | 1 (4) |
| More than one site | 3 (12) |
| Other | 6 (25) |
| Primary site status at study entry | |
| Eradicated, no recurrence | 6 (25) |
| Eradicated, but recurred locally | 5 (21) |
| Residual disease after prior therapy | 12 (50) |
| Untreated | 1 (4) |
| Status of regional lymph nodes | |
| Never involved | 14 (64) |
| Never involved, but removed prophylactically | 3 (14) |
| Involved nodes eradicated | 2 (9) |
| Involved nodes eradicated, but new involvement | 1 (4) |
| Involved nodes not treated | 2 (9) |
| Unknown | 2 |
| Metastatic site involvement | |
| Lung | 22 (92) |
| Liver | 7 (31) |
| Bone | 1 (4) |
| Soft tissue | 2 (8) |
| Prior Treatment | |
| Chemotherapy | 10 (42) |
| Radiation therapy | 23 (96) |
| Surgery | 21 (86) |
a
except for age where actual age is shown.
NOS, not otherwise specified